Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial

PURPOSE: Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus chemotherapy. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooki, Akira, Morita, Satoshi, Tsuji, Akihito, Iwamoto, Shigeyoshi, Hara, Hiroki, Tanioka, Hiroaki, Satake, Hironaga, Kataoka, Masato, Kotaka, Masahito, Kagawa, Yoshinori, Nakamura, Masato, Shingai, Tatsushi, Ishikawa, Masashi, Miyake, Yasuhiro, Suto, Takeshi, Hashiguchi, Yojiro, Yabuno, Taichi, Ando, Masahiko, Sakamoto, Junichi, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238042/
https://www.ncbi.nlm.nih.gov/pubmed/35765021
http://dx.doi.org/10.1186/s12885-022-09811-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238042/
https://www.ncbi.nlm.nih.gov/pubmed/35765021
http://dx.doi.org/10.1186/s12885-022-09811-x

Ejemplares similares